Skip to main content

Table 1 Characteristics of the patients enrolled in the study

From: Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years

Patient ID

Phenotype

Type of mutation

Age at diagnosis

Age at start of ERT

Group A

A1

Severe

Intragenic deletion

0.9

1.6

A2

Severe

Missense

1.0

1.6

A3

Severe

Missense

2.2

2.3

A4

Attenuated

Small deletion

1.8

2.4

A5

Attenuated

Splicing mutation

2.4

2.6

A6

Severe

Small deletion

2.8

2.9

A7

Attenuated

Two in cis missense

1.3

3.3

A8

Severe

Missense

2.8

3.4

A9

Severe

Splicing mutation

3.2

3.4

A10

Attenuated

Two in cis missense

n.a.

3.7

A11

Severe

Missense

3.5

3.7

A12

Severe

Missense

4.4

4.7

A13

Severe

Missense

4.7

5.0

Group B

B1

Severe

Small deletion

2.5

5.3

B2

Attenuated

Nonsense

n.a.

6.9

B3

Severe

Missense

2.2

7.7

B4

Severe

Recombination

3.1

8.0

B5

Attenuated

Nonsense

4.5

9.0

B6

Severe

Missense

7.1

9.2

B7

Severe

Missense

7.8

11.4

Group C

C1

Severe

Missense

4.3

12.7

C2

Severe

Nonsense

4.0

15.8

C3

Attenuated

Missense

3.8

16.3

C4

Attenuated

n.i.

6.8

16.7

C5

Attenuated

Missense

15.5

18.7

C6

Attenuated

Missense

15.2

18.8

C7

Severe

Nonsense

4.1

27.0

  1. Age at start of ERT: group A ≤5 years, group B >5 and ≤ 12 years, group C >12 years (n.i. = not identified).